基本信息

产品名称	Icrucumab (anti-FLT1), 血管内皮生长因子受体 1 拮抗剂
别名	伊库单抗（抗-FLT1）
英文别名	EC 2.7.10.1 \| FLT \| FLT-1 \| Fms-like tyrosine kinase 1 \| Tyrosine-protein kinase FRT \| Tyrosine-protein kinase receptor FLT \| Vascular permeability factor receptor \| VEGFR-1
规格或纯度	无载体, 重组, ExactAb™, 低内毒素, 无叠氮钠, 已验证, 无动物源, ≥95%(SDS-PAGE&SEC-HPLC), 见COA
宿主种属	人(Human)
特异性	FLT1
种属反应性	人(Human)
偶联	Unconjugated
作用类型	拮抗剂
作用机制	血管内皮生长因子受体 1 拮抗剂

产品属性

克隆类型	重组抗体
Format	Whole IgG
亚型	Human IgG1
轻链亚型	kappa
SDS-PAGE	146.8kDa
纯化方法	Protein A purified
纯度	>95%
物理外观	Liquid
储存缓冲液	Supplied as a 0.22μm filtered solution in 100mM Pro-Ac, 20mM Arg, pH 5.0
防腐剂	No
浓度	见COA
储存温度	-80℃储存,避免反复冻融
运输条件	超低温冰袋运输
稳定性与储存	在 -80℃ 下保存 24 个月。收货后建议分装。避免冷冻/解冻循环。
CAS编号和信息	1024603-92-6
分子类型	抗体

图片

ELISA: Icrucumab (anti-FLT1) (Ab176053)

Icrucumab (anti-FLT1) (Ab176053) - ELISA
Immobilized Human VEGFR1/FLT1-his is at 2.0 μg/mL can bind Icrucumab (anti-FLT1) (Ab176053) with the EC₅₀ of 15.19 ng/mL.

SEC: Icrucumab (anti-FLT1) (Ab176053)

Icrucumab (anti-FLT1) (Ab176053) - SEC
The purity of Icrucumab (anti-FLT1) (Ab176053) is more than 95% verified by HPLC.

关联靶点（人）

DAZAP1 Tbio DAZ相关蛋白1(DAZ-associated protein 1) (0 活性数据)

点击查看靶蛋白信息： DAZAP1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

FLT1 Tclin 血管内皮生长因子受体 1(Vascular endothelial growth factor receptor 1) (0 活性数据)

点击查看靶蛋白信息： FLT1

活性类型	活性值-log(M)	作用机制	期刊	参考文献(PubMed IDs)

FLT1 Tclin Vascular endothelial growth factor receptor 1 (6262 活性数据)

点击查看靶蛋白信息： FLT1

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

FLT1 Tclin Vascular endothelial growth factor receptor (287 活性数据)

点击查看靶蛋白信息： FLT1

活性类型	Relation	Activity value	Units	Action Type	期刊	PubMed Id	doi	Assay Aladdin ID

作用机制

作用机制	Action Type	target ID	Target Name	Target Type	Target Organism	Binding Site Name	参考文献

安全和危险性（GHS）

SDS英文版

质量标准

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

C of A & Other Certificates(BSE/TSE, COO):

输入批号以搜索分析图谱:

通过匹配包装上的批号来查找并下载产品的 COA，每批产品都进行了严格的验证，您可放心使用！

找到6个结果

批号(Lot Number)	证书类型	日期	货号
ZJ24F1114547	分析证书	24-11-28	Ab176053
ZJ24F1114546	分析证书	24-11-28	Ab176053
ZJ24F1114545	分析证书	24-11-28	Ab176053
ZJ24F0404247	分析证书	24-04-08	Ab176053
ZJ24F0404246	分析证书	24-04-08	Ab176053
ZJ24F0404245	分析证书	24-04-08	Ab176053

可替换产品

参考文献

1. Zhou W, Hur W, McDermott U, Dutt A, Xian W, Ficarro SB, Zhang J, Sharma SV, Brugge J, Meyerson M et al.. (2010) A structure-guided approach to creating covalent FGFR inhibitors.. Chem Biol, 17 (3): (285-95). [PMID:20338520]
2. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS et al.. (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.. Mol Cancer Ther, 5 (4): (995-1006). [PMID:16648571]
3. Manley PW, Furet P, Bold G, Brüggen J, Mestan J, Meyer T, Schnell CR, Wood J, Haberey M, Huth A et al.. (2002) Anthranilic acid amides: a novel class of antiangiogenic VEGF receptor kinase inhibitors.. J Med Chem, 45 (26): (5687-93). [PMID:12477352]
4. Bold G, Altmann KH, Frei J, Lang M, Manley PW, Traxler P, Wietfeld B, Brüggen J, Buchdunger E, Cozens R et al.. (2000) New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis.. J Med Chem, 43 (12): (2310-23). [PMID:10882357]
5. Zhou Y, Chen Y, Tong L, Xie H, Wen W, Zhang J, Xi Y, Shen Y, Geng M, Wang Y et al.. (2012) AL3810, a multi-tyrosine kinase inhibitor, exhibits potent anti-angiogenic and anti-tumour activity via targeting VEGFR, FGFR and PDGFR.. J Cell Mol Med, 16 (10): (2321-30). [PMID:22304225]
6. Hennequin LF, Allen J, Breed J, Curwen J, Fennell M, Green TP, Lambert-van der Brempt C, Morgentin R, Norman RA, Olivier A et al.. (2006) N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor.. J Med Chem, 49 (22): (6465-88). [PMID:17064066]
7. Galkin AV, Melnick JS, Kim S, Hood TL, Li N, Li L, Xia G, Steensma R, Chopiuk G, Jiang J et al.. (2007) Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.. Proc Natl Acad Sci USA, 104 (1): (270-5). [PMID:17185414]
8. Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY. (2012) Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.. Bioorg Med Chem Lett, 22 (23): (7232-6). [PMID:23099099]
9. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al.. (2006) Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity.. J Med Chem, 49 (12): (3563-80). [PMID:16759099]
10. Pan BS, Chan GK, Chenard M, Chi A, Davis LJ, Deshmukh SV, Gibbs JB, Gil S, Hang G, Hatch H et al.. (2010) MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.. Cancer Res, 70 (4): (1524-33). [PMID:20145145]
11. Machrouhi F, Ouhamou N, Laderoute K, Calaoagan J, Bukhtiyarova M, Ehrlich PJ, Klon AE. (2010) The rational design of a novel potent analogue of the 5'-AMP-activated protein kinase inhibitor compound C with improved selectivity and cellular activity.. Bioorg Med Chem Lett, 20 (22): (6394-9). [PMID:20932747]
12. Trudel S, Li ZH, Wei E, Wiesmann M, Chang H, Chen C, Reece D, Heise C, Stewart AK. (2005) CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.. Blood, 105 (7): (2941-8). [PMID:15598814]
13. Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M et al.. (2004) BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.. Cancer Res, 64 (19): (7099-109). [PMID:15466206]
14. Millan DS, Bunnage ME, Burrows JL, Butcher KJ, Dodd PG, Evans TJ, Fairman DA, Hughes SJ, Kilty IC, Lemaitre A et al.. (2011) Design and synthesis of inhaled p38 inhibitors for the treatment of chronic obstructive pulmonary disease.. J Med Chem, 54 (22): (7797-814). [PMID:21888439]
15. Hudkins RL, Becknell NC, Zulli AL, Underiner TL, Angeles TS, Aimone LD, Albom MS, Chang H, Miknyoczki SJ, Hunter K et al.. (2012) Synthesis and biological profile of the pan-vascular endothelial growth factor receptor/tyrosine kinase with immunoglobulin and epidermal growth factor-like homology domains 2 (VEGF-R/TIE-2) inhibitor 11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo[5,4-a]pyrrolo[3,4-c]carbazol-4-one (CEP-11981): a novel oncology therapeutic agent.. J Med Chem, 55 (2): (903-13). [PMID:22148921]
16. Antczak C, Mahida JP, Bhinder B, Calder PA, Djaballah H. (2012) A high-content biosensor-based screen identifies cell-permeable activators and inhibitors of EGFR function: implications in drug discovery.. J Biomol Screen, 17 (7): (885-99). [PMID:22573732]
17. Hennequin LF, Thomas AP, Johnstone C, Stokes ES, Plé PA, Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO et al.. (1999) Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 42 (26): (5369-89). [PMID:10639280]
18. Tap WD, Wainberg ZA, Anthony SP, Ibrahim PN, Zhang C, Healey JH, Chmielowski B, Staddon AP, Cohn AL, Shapiro GI et al.. (2015) Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.. N Engl J Med, 373 (5): (428-37). [PMID:26222558]
19. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al.. (2011) Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.. Bioorg Med Chem Lett, 21 (21): (6258-63). [PMID:21958547]
20. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al.. (2015) Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders.. J Med Chem, 58 (23): (9154-70). [PMID:26509640]
21. Glaser KB, Li J, Marcotte PA, Magoc TJ, Guo J, Reuter DR, Tapang P, Wei RQ, Pease LJ, Bui MH et al.. (2012) Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.. J Pharmacol Exp Ther, 343 (3): (617-27). [PMID:22935731]
22. Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S et al.. (2016) Pexmetinib: A Novel Dual Inhibitor of Tie2 and p38 MAPK with Efficacy in Preclinical Models of Myelodysplastic Syndromes and Acute Myeloid Leukemia.. Cancer Res, 76 (16): (4841-4849). [PMID:27287719]
23. Patwardhan PP, Ivy KS, Musi E, de Stanchina E, Schwartz GK. (2016) Significant blockade of multiple receptor tyrosine kinases by MGCD516 (Sitravatinib), a novel small molecule inhibitor, shows potent anti-tumor activity in preclinical models of sarcoma.. Oncotarget, 7 (4): (4093-109). [PMID:26675259]
24. Li Y, Xiong Y, Zhang G, Zhang L, Yang W, Yang J, Huang L, Qiao Z, Miao Z, Lin G et al.. (2018) Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.. J Med Chem, 61 (24): (11398-11414). [PMID:30480444]
25. Zhang J, Jiang X, Jiang Y, Guo M, Zhang S, Li J, He J, Liu J, Wang J, Ouyang L. (2016) Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.. Eur J Med Chem, 108 (495-504). [PMID:26717201]
26. Zhou Y, Shan S, Li ZB, Xin LJ, Pan DS, Yang QJ, Liu YP, Yue XP, Liu XR, Gao JZ et al.. (2017) CS2164, a novel multi-target inhibitor against tumor angiogenesis, mitosis and chronic inflammation with anti-tumor potency.. Cancer Sci, 108 (3): (469-477). [PMID:28004478]
27. Yang T, Hu M, Qi W, Yang Z, Tang M, He J, Chen Y, Bai P, Yuan X, Zhang C et al.. (2019) Discovery of Potent and Orally Effective Dual Janus Kinase 2/FLT3 Inhibitors for the Treatment of Acute Myelogenous Leukemia and Myeloproliferative Neoplasms.. J Med Chem, 62 (22): (10305-10320). [PMID:31670517]
28. Jarvis A, Allerston CK, Jia H, Herzog B, Garza-Garcia A, Winfield N, Ellard K, Aqil R, Lynch R, Chapman C et al.. (2010) Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor A (VEGF-A) interaction.. J Med Chem, 53 (5): (2215-26). [PMID:20151671]
29. Tadesse S, Yu M, Mekonnen LB, Lam F, Islam S, Tomusange K, Rahaman MH, Noll B, Basnet SK, Teo T et al.. (2017) Highly Potent, Selective, and Orally Bioavailable 4-Thiazol-N-(pyridin-2-yl)pyrimidin-2-amine Cyclin-Dependent Kinases 4 and 6 Inhibitors as Anticancer Drug Candidates: Design, Synthesis, and Evaluation.. J Med Chem, 60 (5): (1892-1915). [PMID:28156111]
30. Sung Hee Hwang, Aaron T Wecksler, Guodong Zhang, Christophe Morisseau, Long V Nguyen, Samuel H Fu, Bruce D Hammock,. (2013-06-04) Synthesis and biological evaluation of sorafenib- and regorafenib-like sEH inhibitors.. Bioorganic & medicinal chemistry letters, 23 ((13)): ( 3732-3737 ). [PMID:23726028]
31. Bing Yu,Li-da Tang,Yi-Liang Li,Shu-Hui Song,Xiao-Liang Ji,Mu-Sen Lin,Chun-Fu Wu. (2011-12-16) Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.. Bioorganic & medicinal chemistry letters, 22 ((1)): (110-114). [PMID:22169262]
32. Hennequin LF, Stokes ES, Thomas AP, Johnstone C, Plé PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO.. (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors.. J Med Chem, 45 (6): (1300-1312). [PMID:11881999] [10.1021/jm011022e]
33. Borzilleri RM, Zheng X, Qian L, Ellis C, Cai ZW, Wautlet BS, Mortillo S, Jeyaseelan R, Kukral DW, Fura A, Kamath A, Vyas V, Tokarski JS, Barrish JC, Hunt JT, Lombardo LJ, Fargnoli J, Bhide RS.. (2005) Design, synthesis, and evaluation of orally active 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines as dual vascular endothelial growth factor receptor-2 and fibroblast growth factor receptor-1 inhibitors.. J Med Chem, 48 (12): (3991-4008). [PMID:15943473] [10.1021/jm0501275]
34. Kuo GH, Wang A, Emanuel S, Deangelis A, Zhang R, Connolly PJ, Murray WV, Gruninger RH, Sechler J, Fuentes-Pesquera A, Johnson D, Middleton SA, Jolliffe L, Chen X.. (2005) Synthesis and discovery of pyrazine-pyridine biheteroaryl as a novel series of potent vascular endothelial growth factor receptor-2 inhibitors.. J Med Chem, 48 (6): (1886-1900). [PMID:15771433] [10.1021/jm040099a]
35. Borzilleri RM, Bhide RS, Barrish JC, D'Arienzo CJ, Derbin GM, Fargnoli J, Hunt JT, Jeyaseelan R, Kamath A, Kukral DW, Marathe P, Mortillo S, Qian L, Tokarski JS, Wautlet BS, Zheng X, Lombardo LJ.. (2006) Discovery and evaluation of N-cyclopropyl- 2,4-difluoro-5-((2-(pyridin-2-ylamino)thiazol-5- ylmethyl)amino)benzamide (BMS-605541), a selective and orally efficacious inhibitor of vascular endothelial growth factor receptor-2.. J Med Chem, 49 (13): (3766-3769). [PMID:16789733] [10.1021/jm060347y]
36. Dinges J, Albert DH, Arnold LD, Ashworth KL, Akritopoulou-Zanze I, Bousquet PF, Bouska JJ, Cunha GA, Davidsen SK, Diaz GJ, Djuric SW, Gasiecki AF, Gintant GA, Gracias VJ, Harris CM, Houseman KA, Hutchins CW, Johnson EF, Li H, Marcotte PA, Martin RL, Michaelides MR, Nyein M, Sowin TJ, Su Z, Tapang PH, Xia Z, Zhang HQ.. (2007) 1,4-Dihydroindeno[1,2-c]pyrazoles with acetylenic side chains as novel and potent multitargeted receptor tyrosine kinase inhibitors with low affinity for the hERG ion channel.. J Med Chem, 50 (9): (2011-2029). [PMID:17425296] [10.1021/jm061223o]
37. Ji Z, Ahmed AA, Albert DH, Bouska JJ, Bousquet PF, Cunha GA, Diaz G, Glaser KB, Guo J, Harris CM, Li J, Marcotte PA, Moskey MD, Oie T, Pease L, Soni NB, Stewart KD, Davidsen SK, Michaelides MR.. (2008) 3-amino-benzo[d]isoxazoles as novel multitargeted inhibitors of receptor tyrosine kinases.. J Med Chem, 51 (5): (1231-1241). [PMID:18260617] [10.1021/jm701096v]
38. Weiss MM, Harmange JC, Polverino AJ, Bauer D, Berry L, Berry V, Borg G, Bready J, Chen D, Choquette D, Coxon A, DeMelfi T, Doerr N, Estrada J, Flynn J, Graceffa RF, Harriman SP, Kaufman S, La DS, Long A, Neervannan S, Patel VF, Potashman M, Regal K, Roveto PM, Schrag ML, Starnes C, Tasker A, Teffera Y, Whittington DA, Zanon R.. (2008) Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.. J Med Chem, 51 (6): (1668-1680). [PMID:18324759] [10.1021/jm701098w]
39. McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, Rothenberg SM, Supko JG, Sordella R, Ulkus LE, Iafrate AJ, Maheswaran S, Njauw CN, Tsao H, Drew L, Hanke JH, Ma XJ, Erlander MG, Gray NS, Haber DA, Settleman J.. (2007) Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling.. Proc Natl Acad Sci U S A, 104 (50): (19936-19941). [PMID:18077425] [10.1073/pnas.0707498104]
40. D'Angelo ND, Bellon SF, Booker SK, Cheng Y, Coxon A, Dominguez C, Fellows I, Hoffman D, Hungate R, Kaplan-Lefko P, Lee MR, Li C, Liu L, Rainbeau E, Reider PJ, Rex K, Siegmund A, Sun Y, Tasker AS, Xi N, Xu S, Yang Y, Zhang Y, Burgess TL, Dussault I, Kim TS.. (2008) Design, synthesis, and biological evaluation of potent c-Met inhibitors.. J Med Chem, 51 (18): (5766-5779). [PMID:18763753] [10.1021/jm8006189]
41. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH.. (2009) Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor.. Bioorg Med Chem Lett, 19 (16): (4720-4723). [PMID:19596575] [10.1016/j.bmcl.2009.06.066]
42. Gangjee A, Namjoshi OA, Ihnat MA, Buchanan A.. (2010) The contribution of a 2-amino group on receptor tyrosine kinase inhibition and antiangiogenic activity in 4-anilinosubstituted pyrrolo[2,3-d]pyrimidines.. Bioorg Med Chem Lett, 20 (10): (3177-3181). [PMID:20403693] [10.1016/j.bmcl.2010.03.064]
43. Bavetsias V, Large JM, Sun C, Bouloc N, Kosmopoulou M, Matteucci M, Wilsher NE, Martins V, Reynisson J, Atrash B, Faisal A, Urban F, Valenti M, de Haven Brandon A, Box G, Raynaud FI, Workman P, Eccles SA, Bayliss R, Blagg J, Linardopoulos S, McDonald E.. (2010) Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.. J Med Chem, 53 (14): (5213-5228). [PMID:20565112] [10.1021/jm100262j]
44. Lin WH, Hsieh SY, Yen SC, Chen CT, Yeh TK, Hsu T, Lu CT, Chen CP, Chen CW, Chou LH, Huang YL, Cheng AH, Chang YI, Tseng YJ, Yen KR, Chao YS, Hsu JT, Jiaang WT.. (2011) Discovery and evaluation of 3-phenyl-1H-5-pyrazolylamine-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 19 (14): (4173-4182). [PMID:21708468] [10.1016/j.bmc.2011.06.016]
45. Lumeras W, Vidal L, Vidal B, Balagué C, Orellana A, Maldonado M, Domínguez M, Segarra V, Caturla F.. (2011) 1,7-Naphthyridine 1-oxides as novel potent and selective inhibitors of p38 mitogen activated protein kinase.. J Med Chem, 54 (22): (7899-7910). [PMID:21999461] [10.1021/jm200975u]
46. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K.. (2011) Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold.. J Med Chem, 54 (23): (8030-8050). [PMID:22003817] [10.1021/jm2008634]
47. Gangjee A, Zaware N, Raghavan S, Yang J, Thorpe JE, Ihnat MA.. (2012) N⁴-(3-Bromophenyl)-7-(substituted benzyl) pyrrolo[2,3-d]pyrimidines as potent multiple receptor tyrosine kinase inhibitors: design, synthesis, and in vivo evaluation.. Bioorg Med Chem, 20 (7): (2444-2454). [PMID:22370340] [10.1016/j.bmc.2012.01.029]
48. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY.. (2012) Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo.. J Med Chem, 55 (8): (3852-3866). [PMID:22452518] [10.1021/jm300042x]
49. Lin X, Huang XP, Chen G, Whaley R, Peng S, Wang Y, Zhang G, Wang SX, Wang S, Roth BL, Huang N.. (2012) Life beyond kinases: structure-based discovery of sorafenib as nanomolar antagonist of 5-HT receptors.. J Med Chem, 55 (12): (5749-5759). [PMID:22694093] [10.1021/jm300338m]
50. Bavetsias V, Crumpler S, Sun C, Avery S, Atrash B, Faisal A, Moore AS, Kosmopoulou M, Brown N, Sheldrake PW, Bush K, Henley A, Box G, Valenti M, de Haven Brandon A, Raynaud FI, Workman P, Eccles SA, Bayliss R, Linardopoulos S, Blagg J.. (2012) Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.. J Med Chem, 55 (20): (8721-8734). [PMID:23043539] [10.1021/jm300952s]
51. Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.. (2013) Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).. Eur J Med Chem, 61 (95-103). [PMID:23047001] [10.1016/j.ejmech.2012.09.021]
52. Gangjee A, Namjoshi OA, Yu J, Ihnat MA, Thorpe JE, Bailey-Downs LC.. (2013) N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.. Bioorg Med Chem, 21 (5): (1312-1323). [PMID:23375090] [10.1016/j.bmc.2012.12.045]
53. Lin WH, Hsu JT, Hsieh SY, Chen CT, Song JS, Yen SC, Hsu T, Lu CT, Chen CH, Chou LH, Yang YN, Chiu CH, Chen CP, Tseng YJ, Yen KJ, Yeh CF, Chao YS, Yeh TK, Jiaang WT.. (2013) Discovery of 3-phenyl-1H-5-pyrazolylamine derivatives containing a urea pharmacophore as potent and efficacious inhibitors of FMS-like tyrosine kinase-3 (FLT3).. Bioorg Med Chem, 21 (11): (2856-2867). [PMID:23618709] [10.1016/j.bmc.2013.03.083]
54. Salado IG, Redondo M, Bello ML, Perez C, Liachko NF, Kraemer BC, Miguel L, Lecourtois M, Gil C, Martinez A, Perez DI.. (2014) Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.. J Med Chem, 57 (6): (2755-2772). [PMID:24592867] [10.1021/jm500065f]
55. Gogate PN, Ethirajan M, Kurenova EV, Magis AT, Pandey RK, Cance WG.. (2014) Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.. Eur J Med Chem, 80 (154-166). [PMID:24780592] [10.1016/j.ejmech.2014.04.041]
56. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L.. (2015) In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor.. Eur J Med Chem, 89 (310-319). [PMID:25462247] [10.1016/j.ejmech.2014.10.044]
57. Eldehna WM, Ibrahim HS, Abdel-Aziz HA, Farrag NN, Youssef MM.. (2015) Design, synthesis and in vitro antitumor activity of novel N-substituted-4-phenyl/benzylphthalazin-1-ones.. Eur J Med Chem, 89 (549-560). [PMID:25462265] [10.1016/j.ejmech.2014.10.064]
58. Song Z, Yang Y, Liu Z, Peng X, Guo J, Yang X, Wu K, Ai J, Ding J, Geng M, Zhang A.. (2015) Discovery of novel 2,4-diarylaminopyrimidine analogues (DAAPalogues) showing potent inhibitory activities against both wild-type and mutant ALK kinases.. J Med Chem, 58 (1): (197-211). [PMID:24785465] [10.1021/jm5005144]
59. Roth GJ, Binder R, Colbatzky F, Dallinger C, Schlenker-Herceg R, Hilberg F, Wollin SL, Kaiser R.. (2015) Nintedanib: from discovery to the clinic.. J Med Chem, 58 (3): (1053-1063). [PMID:25474320] [10.1021/jm501562a]
60. Yadav RR, Sharma S, Joshi P, Wani A, Vishwakarma RA, Kumar A, Bharate SB.. (2015) Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents.. Bioorg Med Chem Lett, 25 (15): (2948-2952). [PMID:26048785] [10.1016/j.bmcl.2015.05.034]
61. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY.. (2015) Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors.. Bioorg Med Chem Lett, 25 (20): (4534-4538). [PMID:26342867] [10.1016/j.bmcl.2015.08.068]
62. Ravez S, Arsenlis S, Barczyk A, Dupont A, Frédérick R, Hesse S, Kirsch G, Depreux P, Goossens L.. (2015) Synthesis and biological evaluation of di-aryl urea derivatives as c-Kit inhibitors.. Bioorg Med Chem, 23 (22): (7340-7347). [PMID:26526740] [10.1016/j.bmc.2015.10.035]
63. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J.. (2016) 8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors.. J Med Chem, 59 (4): (1388-1409). [PMID:26741168] [10.1021/acs.jmedchem.5b01635]
64. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A.. (2016) Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors.. J Med Chem, 59 (8): (3886-3905). [PMID:27010810] [10.1021/acs.jmedchem.6b00087]
65. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L.. (2017) Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3).. Eur J Med Chem, 127 (72-86). [PMID:28038328] [10.1016/j.ejmech.2016.12.038]
66. Lu Y, Mao F, Li X, Zheng X, Wang M, Xu Q, Zhu J, Li J.. (2017) Discovery of Potent, Selective Stem Cell Factor Receptor/Platelet Derived Growth Factor Receptor Alpha (c-KIT/PDGFRα) Dual Inhibitor for the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors (GISTs).. J Med Chem, 60 (12): (5099-5119). [PMID:28541695] [10.1021/acs.jmedchem.7b00468]
67. Zhu W, Chen H, Wang Y, Wang J, Peng X, Chen X, Gao Y, Li C, He Y, Ai J, Geng M, Zheng M, Liu H.. (2017) Design, Synthesis, and Pharmacological Evaluation of Novel Multisubstituted Pyridin-3-amine Derivatives as Multitargeted Protein Kinase Inhibitors for the Treatment of Non-Small Cell Lung Cancer.. J Med Chem, 60 (14): (6018-6035). [PMID:28714692] [10.1021/acs.jmedchem.7b00076]
68. Zhao F, Zhang LD, Hao Y, Chen N, Bai R, Wang YJ, Zhang CC, Li GS, Hao LJ, Shi C, Zhang J, Mao Y, Fan Y, Xia GX, Yu JX, Liu YJ.. (2017) Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.. Eur J Med Chem, 134 (147-158). [PMID:28411455] [10.1016/j.ejmech.2017.03.085]
69. Wagman AS, Boyce RS, Brown SP, Fang E, Goff D, Jansen JM, Le VP, Levine BH, Ng SC, Ni ZJ, Nuss JM, Pfister KB, Ramurthy S, Renhowe PA, Ring DB, Shu W, Subramanian S, Zhou XA, Shafer CM, Harrison SD, Johnson KW, Bussiere DE.. (2017) Synthesis, Binding Mode, and Antihyperglycemic Activity of Potent and Selective (5-Imidazol-2-yl-4-phenylpyrimidin-2-yl)[2-(2-pyridylamino)ethyl]amine Inhibitors of Glycogen Synthase Kinase 3.. J Med Chem, 60 (20): (8482-8514). [PMID:29016121] [10.1021/acs.jmedchem.7b00922]
70. Patel HM, Pawara R, Ansari A, Noolvi M, Surana S.. (2017) Design and synthesis of quinazolinones as EGFR inhibitors to overcome EGFR resistance obstacle.. Bioorg Med Chem, 25 (10): (2713-2723). [PMID:28366268] [10.1016/j.bmc.2017.03.039]
71. Zhang Y, Chen Y, Zhang D, Wang L, Lu T, Jiao Y.. (2018) Discovery of Novel Potent VEGFR-2 Inhibitors Exerting Significant Antiproliferative Activity against Cancer Cell Lines.. J Med Chem, 61 (1): (140-157). [PMID:29189002] [10.1021/acs.jmedchem.7b01091]
72. Gouda AM, Abdelazeem AH, Omar HA, Abdalla AN, Abourehab MAS, Ali HI.. (2017) Pyrrolizines: Design, synthesis, anticancer evaluation and investigation of the potential mechanism of action.. Bioorg Med Chem, 25 (20): (5637-5651). [PMID:28916158] [10.1016/j.bmc.2017.08.039]
73. Bhide RS, Keon A, Weigelt C, Sack JS, Schmidt RJ, Lin S, Xiao HY, Spergel SH, Kempson J, Pitts WJ, Carman J, Poss MA.. (2017) Discovery and structure-based design of 4,6-diaminonicotinamides as potent and selective IRAK4 inhibitors.. Bioorg Med Chem Lett, 27 (21): (4908-4913). [PMID:28947151] [10.1016/j.bmcl.2017.09.029]
74. Wang Y, Zhi Y, Jin Q, Lu S, Lin G, Yuan H, Yang T, Wang Z, Yao C, Ling J, Guo H, Li T, Jin J, Li B, Zhang L, Chen Y, Lu T.. (2018) Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia.. J Med Chem, 61 (4): (1499-1518). [PMID:29357250] [10.1021/acs.jmedchem.7b01261]
75. Adams CM, Anderson K, Artman G, Bizec JC, Cepeda R, Elliott J, Fassbender E, Ghosh M, Hanks S, Hardegger LA, Hosagrahara VP, Jaffee B, Jendza K, Ji N, Johnson L, Lee W, Liu D, Liu F, Long D, Ma F, Mainolfi N, Meredith EL, Miranda K, Peng Y, Poor S, Powers J, Qiu Y, Rao C, Shen S, Sivak JM, Solovay C, Tarsa P, Woolfenden A, Zhang C, Zhang Y.. (2018) The Discovery of N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-((6- ((methylamino)methyl)pyrimidin-4-yl)oxy)-1H-indole-1-carboxamide (Acrizanib), a VEGFR-2 Inhibitor Specifically Designed for Topical Ocular Delivery, as a Therapy for Neovascular Age-Related Macular Degeneration.. J Med Chem, 61 (4): (1622-1635). [PMID:29400470] [10.1021/acs.jmedchem.7b01731]
76. Fukuda T, Goto R, Kiho T, Ueda K, Muramatsu S, Hashimoto M, Aki A, Watanabe K, Tanaka N.. (2017) Discovery of DS28120313 as a potent orally active hepcidin production inhibitor: Design and optimization of novel 4,6-disubstituted indazole derivatives.. Bioorg Med Chem Lett, 27 (23): (5252-5257). [PMID:29079471] [10.1016/j.bmcl.2017.10.031]
77. Malki WH, Gouda AM, Ali HEA, Al-Rousan R, Samaha D, Abdalla AN, Bustamante J, Abd Elmageed ZY, Ali HI.. (2018) Structural-based design, synthesis, and antitumor activity of novel alloxazine analogues with potential selective kinase inhibition.. Eur J Med Chem, 152 (31-52). [PMID:29684708] [10.1016/j.ejmech.2018.04.029]
78. Zhi Y, Li B, Yao C, Li H, Chen P, Bao J, Qin T, Wang Y, Lu T, Lu S.. (2018) Discovery of the selective and efficacious inhibitors of FLT3 mutations.. Eur J Med Chem, 155 (303-315). [PMID:29894944] [10.1016/j.ejmech.2018.06.010]
79. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V.. (2017) Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1.. Bioorg Med Chem, 25 (24): (6523-6535). [PMID:29089259] [10.1016/j.bmc.2017.10.032]
80. Philip S, Kumarasiri M, Teo T, Yu M, Wang S.. (2018) Cyclin-Dependent Kinase 8: A New Hope in Targeted Cancer Therapy?. J Med Chem, 61 (12): (5073-5092). [PMID:29266937] [10.1021/acs.jmedchem.7b00901]
81. La Pietra V, Sartini S, Botta L, Antonelli A, Ferrari SM, Fallahi P, Moriconi A, Coviello V, Quattrini L, Ke YY, Hsing-Pang H, Da Settimo F, Novellino E, La Motta C, Marinelli L.. (2018) Challenging clinically unresponsive medullary thyroid cancer: Discovery and pharmacological activity of novel RET inhibitors.. Eur J Med Chem, 150 (491-505). [PMID:29549836] [10.1016/j.ejmech.2018.02.080]
82. Zhang Y, Lv H, Luo L, Xu Y, Pan Y, Wang Y, Lin H, Xiong J, Guo P, Zhang J, Li X, Ye F.. (2018) Design, synthesis and pharmacological evaluation of N4,N6-disubstituted pyrimidine-4,6-diamine derivatives as potent EGFR inhibitors in non-small cell lung cancer.. Eur J Med Chem, 157 (1300-1325). [PMID:30195240] [10.1016/j.ejmech.2018.08.031]
83. Song M.. (2017) Recent developments in small molecule therapies for renal cell carcinoma.. Eur J Med Chem, 142 (383-392). [PMID:28844802] [10.1016/j.ejmech.2017.08.007]
84. Nozal V, Martinez A.. (2019) Tau Tubulin Kinase 1 (TTBK1), a new player in the fight against neurodegenerative diseases.. Eur J Med Chem, 161 (39-47). [PMID:30342424] [10.1016/j.ejmech.2018.10.030]
85. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S.. (2019) Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors.. Bioorg Med Chem Lett, 29 (18): (2650-2654). [PMID:31362920] [10.1016/j.bmcl.2019.07.043]
86. Abdelbaset MS, Abdel-Aziz M, Ramadan M, Abdelrahman MH, Abbas Bukhari SN, Ali TFS, Abuo-Rahma GEA.. (2019) Discovery of novel thienoquinoline-2-carboxamide chalcone derivatives as antiproliferative EGFR tyrosine kinase inhibitors.. Bioorg Med Chem, 27 (6): (1076-1086). [PMID:30744932] [10.1016/j.bmc.2019.02.012]
87. Wang Y, Li L, Fan J, Dai Y, Jiang A, Geng M, Ai J, Duan W.. (2018) Discovery of Potent Irreversible Pan-Fibroblast Growth Factor Receptor (FGFR) Inhibitors.. J Med Chem, 61 (20): (9085-9104). [PMID:29522671] [10.1021/acs.jmedchem.7b01843]
88. Wang Q, Dai Y, Ji Y, Shi H, Guo Z, Chen D, Chen Y, Peng X, Gao Y, Wang X, Chen L, Jiang Y, Geng M, Shen J, Ai J, Xiong B.. (2019) Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma.. Eur J Med Chem, 163 (671-689). [PMID:30572178] [10.1016/j.ejmech.2018.12.015]
89. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H.. (2019) Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952.. Bioorg Med Chem Lett, 29 (7): (873-877). [PMID:30755337] [10.1016/j.bmcl.2019.02.006]
90. Mathison CJN, Chianelli D, Rucker PV, Nelson J, Roland J, Huang Z, Yang Y, Jiang J, Xie YF, Epple R, Bursulaya B, Lee C, Gao MY, Shaffer J, Briones S, Sarkisova Y, Galkin A, Li L, Li N, Li C, Hua S, Kasibhatla S, Kinyamu-Akunda J, Kikkawa R, Molteni V, Tellew JE.. (2020) Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.. ACS Med Chem Lett, 11 (4): (558-565). [PMID:32292564] [10.1021/acsmedchemlett.0c00015]
91. Dart ML,Machleidt T,Jost E,Schwinn MK,Robers MB,Shi C,Kirkland TA,Killoran MP,Wilkinson JM,Hartnett JR,Zimmerman K,Wood KV. (2018) Homogeneous Assay for Target Engagement Utilizing Bioluminescent Thermal Shift.. ACS Med Chem Lett, 9 (6.0): (546-551). [PMID:29937980] [10.1021/acsmedchemlett.8b00081]
92. Elwaie TA,Abbas SE,Aly EI,George RF,Ali H,Kraiouchkine N,Abdelwahed KS,Fandy TE,El Sayed KA,Abd Elmageed ZY,Ali HI. (2020) HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability.. J Med Chem, 63 (24.0): (15906-15945). [PMID:33314925] [10.1021/acs.jmedchem.0c01647]
93. Pang H,Wang N,Chai J,Wang X,Zhang Y,Bi Z,Wu W,He G. (2020) Discovery of novel TNNI3K inhibitor suppresses pyroptosis and apoptosis in murine myocardial infarction injury.. Eur J Med Chem, 197 (112314-112314). [PMID:32344181] [10.1016/j.ejmech.2020.112314]
94. Cao DS,Jiang SL,Guan YD,Chen XS,Zhang LX,Zhang Y,Chen AF,Yang JM,Cheng Y. (2020) A multi-scale systems pharmacology approach uncovers the anti-cancer molecular mechanism of Ixabepilone.. Eur J Med Chem, 199 (112421-112421). [PMID:32428794] [10.1016/j.ejmech.2020.112421]
95. Shibuya, M M and 6 more authors.. (1990) Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.. Oncogene, [PMID:2158038]
96. Matsushime, H H, Yoshida, M C MC, Sasaki, M M and Shibuya, M M.. (1987) A possible new member of tyrosine kinase family, human frt sequence, is highly conserved in vertebrates and located on human chromosome 13.. Japanese journal of cancer research : Gann, [PMID:3040650]
97. Kendall, R L RL and Thomas, K A KA.. (1993) Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor.. Proceedings of the National Academy of Sciences of the United States of America, (15): [PMID:8248162]
98. Barleon, B B and 5 more authors.. (1996) Migration of human monocytes in response to vascular endothelial growth factor (VEGF) is mediated via the VEGF receptor flt-1.. Blood, (15): [PMID:8605350]
99. Sawano, A A, Takahashi, T T, Yamaguchi, S S and Shibuya, M M.. (1997) The phosphorylated 1169-tyrosine containing region of flt-1 kinase (VEGFR-1) is a major binding site for PLCgamma.. Biochemical and biophysical research communications, (18): [PMID:9299537]
100. Wiesmann, C C and 5 more authors.. (1997) Crystal structure at 1.7 A resolution of VEGF in complex with domain 2 of the Flt-1 receptor.. Cell, (28): [PMID:9393862]
101. Igarashi, K K and 5 more authors.. (1998) Tyrosine 1213 of Flt-1 is a major binding site of Nck and SHP-2.. Biochemical and biophysical research communications, (8): [PMID:9600074]
102. Ito, N N, Wernstedt, C C, Engström, U U and Claesson-Welsh, L L.. (1998) Identification of vascular endothelial growth factor receptor-1 tyrosine phosphorylation sites and binding of SH2 domain-containing molecules.. The Journal of biological chemistry, (4): [PMID:9722576]
103. Herley, M T MT, Yu, Y Y, Whitney, R G RG and Sato, J D JD.. (1999) Characterization of the VEGF binding site on the Flt-1 receptor.. Biochemical and biophysical research communications, (7): [PMID:10471394]
104. Starovasnik, M A MA and 5 more authors.. (1999) Solution structure of the VEGF-binding domain of Flt-1: comparison of its free and bound states.. Journal of molecular biology, (29): [PMID:10543948]
105. Huang, K K, Andersson, C C, Roomans, G M GM, Ito, N N and Claesson-Welsh, L L.. (2001) Signaling properties of VEGF receptor-1 and -2 homo- and heterodimers.. The international journal of biochemistry & cell biology, [PMID:11312102]
106. Yu, Y Y and 5 more authors.. (2001) Direct identification of a major autophosphorylation site on vascular endothelial growth factor receptor Flt-1 that mediates phosphatidylinositol 3'-kinase binding.. The Biochemical journal, (1): [PMID:11513746]
107. Angelucci, C C, Lama, G G, Iacopino, F F, Maglione, D D and Sica, G G.. (2001) Effect of placenta growth factor-1 on proliferation and release of nitric oxide, cyclic AMP and cyclic GMP in human epithelial cells expressing the FLT-1 receptor.. Growth factors (Chur, Switzerland), [PMID:11811792]
108. Autiero, Monica M and 27 more authors.. (2003) Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1.. Nature medicine, [PMID:12796773]
109. Cai, Jun J and 6 more authors.. (2003) Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells.. Diabetes, [PMID:14633857]
110. O'Farrell, Anne-Marie AM and 17 more authors.. (2003) An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.. Clinical cancer research : an official journal of the American Association for Cancer Research, (15): [PMID:14654525]
111. Christinger, Hans W HW, Fuh, Germaine G, de Vos, Abraham M AM and Wiesmann, Christian C.. (2004) The crystal structure of placental growth factor in complex with domain 2 of vascular endothelial growth factor receptor-1.. The Journal of biological chemistry, (12): [PMID:14684734]
112. Kobayashi, Satsuki S, Sawano, Asako A, Nojima, Yoshihisa Y, Shibuya, Masabumi M and Maru, Yoshiro Y.. (2004) The c-Cbl/CD2AP complex regulates VEGF-induced endocytosis and degradation of Flt-1 (VEGFR-1).. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, [PMID:15001553]
113. Dunham, A A and 125 more authors.. (2004) The DNA sequence and analysis of human chromosome 13.. Nature, (1): [PMID:15057823]
114. Fan, Fan F and 10 more authors.. (2005) Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells.. Oncogene, (14): [PMID:15735759]
115. Meyer, Rosana D RD, Mohammadi, Moosa M and Rahimi, Nader N.. (2006) A single amino acid substitution in the activation loop defines the decoy characteristic of VEGFR-1/FLT-1.. The Journal of biological chemistry, (13): [PMID:16286478]
116. Carlomagno, Francesca F and 6 more authors.. (2006) BAY 43-9006 inhibition of oncogenic RET mutants.. Journal of the National Cancer Institute, (1): [PMID:16507829]
117. Lesslie, D P DP and 10 more authors.. (2006) Vascular endothelial growth factor receptor-1 mediates migration of human colorectal carcinoma cells by activation of Src family kinases.. British journal of cancer, (5): [PMID:16685275]
118. and Shibuya, Masabumi M.. (2006) Differential roles of vascular endothelial growth factor receptor-1 and receptor-2 in angiogenesis.. Journal of biochemistry and molecular biology, (30): [PMID:17002866]
119. Sonpavde, Guru G and Hutson, Thomas E TE.. (2007) Pazopanib: a novel multitargeted tyrosine kinase inhibitor.. Current oncology reports, [PMID:17288876]
120. Roskoski, Robert R.. (2007) Sunitinib: a VEGF and PDGF receptor protein kinase and angiogenesis inhibitor.. Biochemical and biophysical research communications, (4): [PMID:17367763]
121. Yamamoto, Aisaku A and 5 more authors.. (2007) Vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK 222584 inhibits both the induction and elicitation phases of contact hypersensitivity.. The Journal of dermatology, [PMID:17584317]
122. Matsui, Junji J and 7 more authors.. (2008) E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.. International journal of cancer, (1): [PMID:17943726]
123. Tchaikovski, Vadim V, Fellbrich, Guido G and Waltenberger, Johannes J.. (2008) The molecular basis of VEGFR-1 signal transduction pathways in primary human monocytes.. Arteriosclerosis, thrombosis, and vascular biology, [PMID:18079407]
124. Sela, Shay S and 6 more authors.. (2008) A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia.. Circulation research, (20): [PMID:18515749]
125. Cohen, Ezra E W and 13 more authors.. (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, (10): [PMID:18541897]
126. Jin, Pei P and 9 more authors.. (2008) Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis.. Arthritis research & therapy, [PMID:18593464]
127. Lohela, Marja M, Bry, Maija M, Tammela, Tuomas T and Alitalo, Kari K.. (2009) VEGFs and receptors involved in angiogenesis versus lymphangiogenesis.. Current opinion in cell biology, [PMID:19230644]
128. Iyer, Shalini S, Darley, Paula I PI and Acharya, K Ravi KR.. (2010) Structural insights into the binding of vascular endothelial growth factor-B by VEGFR-1(D2): recognition and specificity.. The Journal of biological chemistry, (30): [PMID:20501651]
129. Mezquita, Belén B, Mezquita, Jovita J, Pau, Montserrat M and Mezquita, Cristóbal C.. (2010) A novel intracellular isoform of VEGFR-1 activates Src and promotes cell invasion in MDA-MB-231 breast cancer cells.. Journal of cellular biochemistry, (1): [PMID:20512933]
130. Taylor, A P AP, Leon, E E and Goldenberg, D M DM.. (2010) Placental growth factor (PlGF) enhances breast cancer cell motility by mobilising ERK1/2 phosphorylation and cytoskeletal rearrangement.. British journal of cancer, (29): [PMID:20551949]
131. Wang, Feng F and 5 more authors.. (2011) RACK1 regulates VEGF/Flt1-mediated cell migration via activation of a PI3K/Akt pathway.. The Journal of biological chemistry, (18): [PMID:21212275]
132. and Shibuya, Masabumi M.. (2011) Involvement of Flt-1 (VEGF receptor-1) in cancer and preeclampsia.. Proceedings of the Japan Academy. Series B, Physical and biological sciences, [PMID:21558755]
133. Ahmad, Shakil S and 6 more authors.. (2011) Autocrine activity of soluble Flt-1 controls endothelial cell function and angiogenesis.. Vascular cell, (13): [PMID:21752276]
134. Cai, Jun and 9 more authors.. (2011) γ-Secretase and presenilin mediate cleavage and phosphorylation of vascular endothelial growth factor receptor-1.. The Journal of biological chemistry, (9): [PMID:22016384]
135. Wang, Jing and 6 more authors.. (2020) Brain accumulation of tivozanib is restricted by ABCB1 (P-glycoprotein) and ABCG2 (breast cancer resistance protein) in mice.. International journal of pharmaceutics, (15): [PMID:32234426]
136. Salgia, Nicholas J; Zengin, Zeynep B and Pal, Sumanta K.. (2020) Tivozanib in renal cell carcinoma: a new approach to previously treated disease.. Therapeutic advances in medical oncology, [PMID:32547647]

溶液计算器

摩尔浓度计算器

计算溶液所需的质量、体积或浓度。

质量

浓度

体积

分子量

g/mol

稀释计算器

计算配制储备溶液所需的稀释度。

浓度1（C1）

体积 1 (V1)

浓度 2 (C2)

体积 2 (V2)

复溶计算器

复溶计算器允许您快速计算试剂的体积，以复溶小瓶。只需输入试剂的质量和目标浓度，计算器将确定其余部分。

体积（添加到小瓶中）

质量（小瓶）

所需的复溶浓度

货号 (SKU)	包装规格	是否现货
Ab176053-100μg	100μg	现货
Ab176053-1mg	1mg	现货
Ab176053-5mg	5mg	现货
Ab176053-10mg	10mg	期货

Icrucumab (anti-FLT1), 血管内皮生长因子受体 1 拮抗剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器

Icrucumab (anti-FLT1), 血管内皮生长因子受体 1 拮抗剂

库存信息

库存信息

库存信息

库存信息

基本信息

产品属性

图片

关联靶点（人）

作用机制

安全和危险性（GHS）

质量标准

质检证书（CoA,COO,BSE/TSE 和分析图谱)

相关产品

可替换产品

参考文献

溶液计算器

摩尔浓度计算器

稀释计算器

复溶计算器